Between January and August 2017, Russia exported 13.8 bln RUB worth of pharmaceutical drugs (excluding exports to the EEU countries), which is in monetary terms 7.5% higher than that of the same period of 2017. The dynamics in physical terms are -6%, with 0.32 bln units of pharmaceuticals. If calculated in minimum dosage units (MDU), the dynamics are also negative, -11.5%.

Over the period, Russia was exporting to 77 countries, while in 2017 the number was 90. In particular, Russia did not export to Ecuador and Angola this year, while these two countries accounted for around 3.2% of the export last year. However, there are 15 new countries on the list, in particular Biocad started to export to Panama, Bolivia and others.

Russia does not exports only self-made products. Between January and August 2018, Russian-made pharmaceutical exports amounted to around 59% of the total pharmaceutical export in monetary terms, while it was 64% over the same period in 2017. Among the top 20 Russian exporters, Avexima has the biggest dynamics, with a 28 times increase in monetary terms.

Among the top Russian-made trademarks, Acellbia by Biocad has the biggest dynamics, its export has increased by 7 times. Over the period, it was exported to 7 countries, mainly Asian, including India (34% of the export), Vietnam (27%), and Sri-Lanka (19%.) The export of Gonadotrophin by Endopharm has increased by 4 times, with Uzbekistan accounting to 77%. The Baltic States, in particular Lithuania and Latvia, also account to significant export volumes.

Dynamics of pharmaceutical drug export from Russia (EEU countries excluded) (2016 – 2017, January – August 2018)